Previous 10 | Next 10 |
IMpactMF is the first and only Phase 3 clinical trial to evaluate overall survival as the primary endpoint in R/R MF An interim analysis is expected in the first half of 2025, with a final analysis expected in the first half of 2026 Geron Corporation (Nasdaq: GERN), a late-sta...
2023-12-04 13:50:57 ET Summary Geron Corporation has submitted its New Drug Application (NDA) to the FDA for its lead candidate, imetelstat, for the treatment of transfusion-dependent anemia in adult patients with myelodysplastic syndromes. The FDA has accepted Geron's NDA and wil...
2023-12-04 08:53:19 ET More on Geron Geron Corporation 2023 Q3 - Results - Earnings Call Presentation Geron Corporation (GERN) Q3 2023 Earnings Call Transcript Geron Corporation Stock: Another Buying Opportunity Geron GAAP EPS of -$0.08 beats by $0.02, revenu...
Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of ...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a histo...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2023 Healthcare Conference Tuesday, No...
2023-11-02 16:30:29 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q3 2023 Earnings Call Nov 02, 2023 , 9:00 a.m. ET Operator Continue reading For further details see: Geron (GERN) Q3 2023 Earnings Call Transcript
2023-11-02 13:05:02 ET Geron Corporation (GERN) Q3 2023 Earnings Conference Call November 2, 2023 9:00 am ET Corporate Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications John Scarlett - Chairman, President and Chief Executive...
Subgroup analyses showed consistently higher transfusion independence (TI) response rates than placebo across different risk groups regardless of International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R) or IPSS molecular (IPSS-M) Robust TI rates with imetelstat treatment compared...
2023-11-02 08:03:26 ET More on Geron Geron Corporation Stock: Another Buying Opportunity Geron Corporation: The FDA, Catalysts And New Competition From Old Drugs FDA's Twist In Geron's Telomerase Tale (Rating Downgrade) Geron Q3 2023 Earnings Preview ...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...